Symbols / ANGO $10.87 -0.28% AngioDynamics, Inc.

Healthcare • Medical Instruments & Supplies • United States • NMS
ANGO Chart
About

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Medical Instruments & Su Market Cap 448.03M
Enterprise Value 418.18M Income -27.71M Sales 307.31M
Book/sh 4.24 Cash/sh 1.01 Dividend Yield —
Payout 0.00% Employees 675 IPO —
P/E — Forward P/E -98.82 PEG —
P/S 1.46 P/B 2.56 P/C —
EV/EBITDA -2787.90 EV/Sales 1.36 Quick Ratio 1.20
Current Ratio 2.24 Debt/Eq 6.69 LT Debt/Eq —
EPS (ttm) -0.67 EPS next Y -0.11 EPS Growth —
Revenue Growth 9.00% Earnings 2026-04-02 ROA -4.60%
ROE -15.26% ROIC — Gross Margin 54.58%
Oper. Margin -3.14% Profit Margin -9.02% Shs Outstand 41.22M
Shs Float 34.49M Short Float 4.60% Short Ratio 6.27
Short Interest — 52W High 13.99 52W Low 8.36
Beta 0.45 Avg Volume 535.70K Volume 371.92K
Target Price $19.33 Recom None Prev Close $10.90
Price $10.87 Change -0.28%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.33
Mean price target
2. Current target
$10.87
Latest analyst target
3. DCF / Fair value
$0.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.87
Low
$16.00
High
$24.00
Mean
$19.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-10-03 main Canaccord Genuity Buy → Buy $18
2025-07-16 init Lake Street — → Buy $24
2025-07-16 reit HC Wainwright & Co. Buy → Buy $16
2025-07-16 main Canaccord Genuity Buy → Buy $17
2025-04-07 main HC Wainwright & Co. Buy → Buy $16
2025-01-10 main HC Wainwright & Co. Buy → Buy $15
2025-01-09 main Canaccord Genuity Buy → Buy $15
2024-12-10 reit HC Wainwright & Co. Buy → Buy $14
2024-10-04 reit HC Wainwright & Co. Buy → Buy $14
2024-10-04 main Canaccord Genuity Buy → Buy $12
2024-09-20 reit HC Wainwright & Co. Buy → Buy $14
2024-07-17 main Canaccord Genuity Buy → Buy $13
2024-07-17 reit HC Wainwright & Co. Buy → Buy $14
2024-05-22 reit HC Wainwright & Co. Buy → Buy $14
2024-04-05 up Oppenheimer Perform → Outperform $12
2024-01-09 main Raymond James Outperform → Outperform $10
2024-01-08 main HC Wainwright & Co. Buy → Buy $18
2023-10-06 main Raymond James Outperform → Outperform $12
2023-10-05 main Canaccord Genuity Buy → Buy $17
2023-10-05 main HC Wainwright & Co. Buy → Buy $20
News
RSS: Latest ANGO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-21 LAWRENCE WEISS T Officer — 10,000 $11.81 $118,100
2025-10-13 TROWBRIDGE STEPHEN A Chief Financial Officer — 890 $11.16 $9,932
2025-10-09 CLEMMER JAMES C Chief Executive Officer — 10,000 $11.15 $111,500
2025-07-16 BURGESS LORINDA Director — 17,675 $0.00 $0
2025-07-16 PICCININI LAURA Officer — 32,423 $0.00 $0
2025-07-16 LAWRENCE WEISS T Officer — 30,900 $0.00 $0
2025-07-16 CLEMMER JAMES C Chief Executive Officer — 206,253 $0.00 $0
2025-07-16 NIGHAN WARREN G JR Officer — 29,349 $0.00 $0
2025-07-16 TARNOFF MICHAEL E Director — 17,675 $0.00 $0
2025-07-16 TROWBRIDGE STEPHEN A Chief Financial Officer — 86,997 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Total Revenue
292.50
-3.76%
303.91
-10.28%
338.75
+7.13%
316.22
Operating Revenue
292.50
-3.76%
303.91
-10.28%
338.75
+7.13%
316.22
Cost Of Revenue
134.79
-9.67%
149.22
-9.29%
164.51
+9.32%
150.49
Reconciled Cost Of Revenue
119.31
-11.33%
134.55
-11.72%
152.42
+8.41%
140.60
Gross Profit
157.71
+1.94%
154.70
-11.22%
174.25
+5.14%
165.73
Operating Expense
181.77
-3.59%
188.54
-2.27%
192.93
+4.88%
183.95
Research And Development
26.22
-16.79%
31.51
+5.45%
29.88
-2.78%
30.74
Selling General And Administration
145.23
+0.86%
143.98
-0.19%
144.25
+7.85%
133.75
Selling And Marketing Expense
103.14
+0.31%
102.82
-1.37%
104.25
+9.39%
95.30
General And Administrative Expense
42.09
+2.25%
41.16
+2.90%
40.00
+4.04%
38.45
Other Gand A
42.09
+2.25%
41.16
+2.90%
40.00
+4.04%
38.45
Total Expenses
316.56
-6.28%
337.76
-5.50%
357.43
+6.88%
334.44
Operating Income
-24.06
+28.90%
-33.84
-81.19%
-18.68
-2.54%
-18.22
Total Operating Income As Reported
-39.95
+79.24%
-192.44
-275.99%
-51.18
-79.77%
-28.47
EBITDA
1.74
+128.34%
-6.13
-150.29%
12.19
+9.54%
11.13
Normalized EBITDA
17.63
-88.44%
152.46
+241.10%
44.70
+109.00%
21.39
Reconciled Depreciation
25.80
-6.90%
27.71
-10.24%
30.87
+5.19%
29.35
EBIT
-24.06
+28.90%
-33.84
-81.19%
-18.68
-2.54%
-18.22
Total Unusual Items
-15.89
+89.98%
-158.59
-387.94%
-32.50
-216.97%
-10.25
Total Unusual Items Excluding Goodwill
-15.89
+89.98%
-158.59
-387.94%
-32.50
-216.97%
-10.25
Special Income Charges
-15.89
+89.98%
-158.59
-387.94%
-32.50
-216.97%
-10.25
Other Special Charges
0.71
-97.95%
34.94
+249.49%
10.00
+31.12%
7.62
Impairment Of Capital Assets
0.00
-100.00%
165.74
+1039.16%
14.55
0.00
Restructuring And Mergern Acquisition
15.18
+22.28%
12.41
+56.03%
7.96
+202.59%
2.63
Net Income
-33.99
+81.56%
-184.35
-251.53%
-52.44
-97.54%
-26.55
Pretax Income
-34.03
+82.24%
-191.64
-252.04%
-54.44
-81.77%
-29.95
Net Non Operating Interest Income Expense
0.98
-39.41%
1.61
+159.73%
-2.70
-292.73%
-0.69
Interest Expense Non Operating
—
—
2.70
+292.73%
0.69
Net Interest Income
0.98
-39.41%
1.61
+159.73%
-2.70
-292.73%
-0.69
Interest Expense
—
—
2.70
+292.73%
0.69
Other Income Expense
-10.95
+93.13%
-159.41
-382.24%
-33.06
-199.31%
-11.04
Other Non Operating Income Expenses
4.94
+705.14%
-0.82
-47.47%
-0.55
+29.87%
-0.79
Gain On Sale Of Business
—
—
0.00
0.00
Tax Provision
-0.04
+99.46%
-7.29
-265.36%
-2.00
+41.36%
-3.40
Tax Rate For Calcs
0.00
-97.37%
0.00
+3.69%
0.00
-67.74%
0.00
Tax Effect Of Unusual Items
-0.02
+99.74%
-6.03
-405.95%
-1.19
-2.26%
-1.16
Net Income Including Noncontrolling Interests
-33.99
+81.56%
-184.35
-251.53%
-52.44
-97.54%
-26.55
Net Income From Continuing Operation Net Minority Interest
-33.99
+81.56%
-184.35
-251.53%
-52.44
-97.54%
-26.55
Net Income From Continuing And Discontinued Operation
-33.99
+81.56%
-184.35
-251.53%
-52.44
-97.54%
-26.55
Net Income Continuous Operations
-33.99
+81.56%
-184.35
-251.53%
-52.44
-97.54%
-26.55
Net Income Discontinuous Operations
—
—
—
—
Normalized Income
-18.12
+43.00%
-31.78
-50.42%
-21.13
-21.04%
-17.46
Net Income Common Stockholders
-33.99
+81.56%
-184.35
-251.53%
-52.44
-97.54%
-26.55
Diluted EPS
-0.83
+81.92%
-4.59
-245.11%
-1.33
-95.59%
-0.68
Basic EPS
-0.83
+81.92%
-4.59
-245.11%
-1.33
-95.59%
-0.68
Basic Average Shares
40.85
+1.67%
40.18
+1.78%
39.48
+1.21%
39.01
Diluted Average Shares
40.85
+1.67%
40.18
+1.78%
39.48
+1.21%
39.01
Diluted NI Availto Com Stockholders
-33.99
+81.56%
-184.35
-251.53%
-52.44
-97.54%
-26.55
Amortization
10.32
-20.92%
13.05
-30.56%
18.79
-3.43%
19.46
Amortization Of Intangibles Income Statement
10.32
-20.92%
13.05
-30.56%
18.79
-3.43%
19.46
Depreciation Amortization Depletion Income Statement
10.32
-20.92%
13.05
-30.56%
18.79
-3.43%
19.46
Depreciation And Amortization In Income Statement
10.32
-20.92%
13.05
-30.56%
18.79
-3.43%
19.46
Gain On Sale Of PPE
0.00
-100.00%
54.50
0.00
0.00
Total Other Finance Cost
-0.98
+39.41%
-1.61
-159.73%
2.70
+292.73%
0.69
Line Item Trend 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Total Assets
280.14
-11.81%
317.67
-40.36%
532.64
-3.64%
552.75
Current Assets
168.32
-12.90%
193.25
+18.17%
163.54
+14.09%
143.34
Cash Cash Equivalents And Short Term Investments
55.89
-26.51%
76.06
+70.45%
44.62
+54.80%
28.82
Cash And Cash Equivalents
55.89
-26.51%
76.06
+70.45%
44.62
+54.80%
28.82
Receivables
43.14
-13.74%
50.01
-5.33%
52.83
-6.50%
56.50
Accounts Receivable
42.89
-1.65%
43.61
-17.45%
52.83
+1.00%
52.30
Gross Accounts Receivable
45.10
-1.41%
45.75
-16.78%
54.98
+1.35%
54.24
Allowance For Doubtful Accounts Receivable
-2.21
-3.46%
-2.14
+0.42%
-2.15
-10.88%
-1.94
Other Receivables
0.25
-96.09%
6.40
—
—
Taxes Receivable
—
—
0.00
-100.00%
4.19
Inventory
62.01
+2.29%
60.62
+9.56%
55.33
+7.65%
51.39
Raw Materials
27.50
-10.54%
30.74
+7.17%
28.68
+1.51%
28.25
Work In Process
7.51
+10.88%
6.77
+0.95%
6.71
-6.65%
7.19
Finished Goods
27.00
+16.84%
23.11
+15.90%
19.94
+24.96%
15.96
Prepaid Assets
4.21
+5.51%
3.99
+13.60%
3.52
-20.64%
4.43
Assets Held For Sale Current
—
0.00
-100.00%
6.15
0.00
Other Current Assets
3.07
+19.21%
2.58
+133.85%
1.10
-49.93%
2.20
Total Non Current Assets
111.82
-10.13%
124.42
-66.29%
369.10
-9.85%
409.41
Net PPE
32.30
-9.44%
35.67
-19.64%
44.38
-1.38%
45.01
Gross PPE
103.42
-4.87%
108.70
+5.12%
103.41
+7.64%
96.07
Accumulated Depreciation
-71.12
+2.63%
-73.04
-23.74%
-59.03
-15.58%
-51.07
Properties
0.00
0.00
0.00
0.00
Land And Improvements
0.39
-20.28%
0.49
+0.00%
0.49
+0.00%
0.49
Buildings And Improvements
16.60
-44.84%
30.10
+1.48%
29.66
+0.80%
29.43
Machinery Furniture Equipment
45.63
+3.33%
44.16
-0.66%
44.46
+4.01%
42.74
Construction In Progress
3.79
+43.82%
2.64
+7.94%
2.44
+1.75%
2.40
Other Properties
36.99
+18.14%
31.31
+18.81%
26.36
+25.45%
21.01
Goodwill And Other Intangible Assets
69.12
-10.68%
77.38
-71.38%
270.38
-23.50%
353.44
Goodwill
—
0.00
-100.00%
159.24
-20.80%
201.06
Other Intangible Assets
69.12
-10.68%
77.38
-30.38%
111.14
-27.06%
152.38
Other Non Current Assets
10.40
-8.49%
11.37
-79.07%
54.33
+395.57%
10.96
Total Liabilities Net Minority Interest
97.17
-13.30%
112.08
-27.38%
154.34
+20.33%
128.26
Current Liabilities
76.20
-16.41%
91.16
+8.74%
83.83
+12.78%
74.32
Payables And Accrued Expenses
67.64
-12.57%
77.36
+15.81%
66.80
+6.32%
62.83
Payables
36.06
-19.01%
44.53
+8.81%
40.92
+42.12%
28.80
Accounts Payable
33.29
-11.81%
37.75
-6.66%
40.45
+44.20%
28.05
Other Payable
2.24
-64.20%
6.26
—
—
Current Accrued Expenses
31.57
-3.84%
32.83
+26.89%
25.88
-23.97%
34.03
Pensionand Other Post Retirement Benefit Plans Current
0.80
-46.16%
1.49
+467.18%
0.26
+344.07%
0.06
Total Tax Payable
0.53
+2.12%
0.52
+8.33%
0.48
-36.00%
0.75
Current Debt And Capital Lease Obligation
—
4.73
-67.97%
14.76
+68.06%
8.78
Current Debt
—
4.73
-67.97%
14.76
+68.06%
8.78
Other Current Borrowings
—
4.73
-67.97%
14.76
+68.06%
8.78
Current Deferred Liabilities
0.37
0.00
—
—
Other Current Liabilities
7.39
-2.51%
7.58
+278.52%
2.00
-24.51%
2.65
Total Non Current Liabilities Net Minority Interest
20.98
+0.22%
20.93
-70.32%
70.52
+30.74%
53.94
Long Term Debt And Capital Lease Obligation
—
—
49.82
+99.27%
25.00
Long Term Debt
—
—
49.82
+99.27%
25.00
Non Current Deferred Liabilities
4.07
-16.06%
4.85
-62.13%
12.81
-20.10%
16.04
Non Current Deferred Taxes Liabilities
4.07
-16.06%
4.85
-62.13%
12.81
-20.10%
16.04
Other Non Current Liabilities
16.90
+5.14%
16.08
+103.91%
7.88
-38.88%
12.90
Stockholders Equity
182.97
-11.00%
205.59
-45.65%
378.30
-10.88%
424.49
Common Stock Equity
182.97
-11.00%
205.59
-45.65%
378.30
-10.88%
424.49
Capital Stock
0.39
+0.00%
0.39
+0.79%
0.38
+0.53%
0.38
Common Stock
0.39
+0.00%
0.39
+0.79%
0.38
+0.53%
0.38
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
41.61
+1.98%
40.80
+2.05%
39.98
+1.11%
39.54
Ordinary Shares Number
40.99
+1.39%
40.43
+2.07%
39.61
+1.12%
39.17
Treasury Shares Number
0.61
+65.90%
0.37
+0.00%
0.37
+0.00%
0.37
Additional Paid In Capital
621.19
+1.75%
610.48
+1.88%
599.21
+2.10%
586.88
Retained Earnings
-429.20
-8.60%
-395.20
-87.43%
-210.85
-33.10%
-158.41
Gains Losses Not Affecting Retained Earnings
-2.02
+53.65%
-4.37
+7.58%
-4.72
-448.05%
1.36
Treasury Stock
7.38
+29.17%
5.71
+0.00%
5.71
+0.00%
5.71
Other Equity Adjustments
-2.02
+53.65%
-4.37
+7.58%
-4.72
-448.05%
1.36
Total Equity Gross Minority Interest
182.97
-11.00%
205.59
-45.65%
378.30
-10.88%
424.49
Total Capitalization
182.97
-11.00%
205.59
-51.98%
428.11
-4.76%
449.49
Working Capital
92.13
-9.77%
102.10
+28.08%
79.72
+15.50%
69.02
Invested Capital
182.97
-13.00%
210.31
-52.51%
442.88
-3.36%
458.27
Total Debt
—
4.73
-92.68%
64.58
+91.16%
33.78
Net Debt
—
—
19.96
+302.56%
4.96
Net Tangible Assets
113.85
-11.19%
128.20
+18.80%
107.91
+51.88%
71.05
Tangible Book Value
113.85
-11.19%
128.20
+18.80%
107.91
+51.88%
71.05
Line Item Trend 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Operating Cash Flow
-10.13
+64.03%
-28.16
-36200.00%
0.08
+101.08%
-7.19
Cash Flow From Continuing Operating Activities
-10.13
+64.03%
-28.16
-36200.00%
0.08
+101.08%
-7.19
Net Income From Continuing Operations
-33.99
+81.56%
-184.35
-251.53%
-52.44
-97.54%
-26.55
Depreciation Amortization Depletion
25.80
-6.90%
27.71
-10.24%
30.87
+5.19%
29.35
Depreciation And Amortization
25.80
-6.90%
27.71
-10.24%
30.87
+5.19%
29.35
Other Non Cash Items
2.52
+190.59%
-2.78
-164.86%
4.29
+20.60%
3.56
Stock Based Compensation
9.77
-7.19%
10.53
-5.64%
11.16
+4.36%
10.69
Provisionand Write Offof Assets
0.70
-47.29%
1.33
+90.79%
0.69
+488.98%
0.12
Asset Impairment Charge
0.17
-99.90%
167.45
+1028.39%
14.84
+3695.40%
0.39
Deferred Tax
-0.99
+87.60%
-7.97
-244.79%
-2.31
+37.68%
-3.71
Deferred Income Tax
-0.99
+87.60%
-7.97
-244.79%
-2.31
+37.68%
-3.71
Operating Gains Losses
—
-54.50
—
—
Change In Working Capital
-14.11
-197.86%
14.42
+305.25%
-7.03
+66.62%
-21.05
Change In Receivables
0.02
-99.71%
7.89
+707.70%
-1.30
+92.43%
-17.15
Changes In Account Receivables
0.02
-99.71%
7.89
+707.70%
-1.30
+92.43%
-17.15
Change In Inventory
-1.35
+85.69%
-9.41
-14.78%
-8.20
-193.20%
-2.80
Change In Prepaid Assets
3.09
+126.64%
-11.59
-3592.17%
0.33
+106.62%
-5.01
Change In Payables And Accrued Expense
-15.88
-157.67%
27.53
+1187.10%
2.14
-45.32%
3.91
Change In Payable
-15.88
-157.67%
27.53
+1187.10%
2.14
-45.32%
3.91
Change In Account Payable
-15.88
-157.67%
27.53
+1187.10%
2.14
-45.32%
3.91
Investing Cash Flow
-10.18
-108.23%
123.72
+1369.41%
-9.75
+49.52%
-19.31
Cash Flow From Continuing Investing Activities
-10.18
-108.23%
123.72
+1369.41%
-9.75
+49.52%
-19.31
Cash From Discontinued Investing Activities
—
—
—
—
Net PPE Purchase And Sale
-4.46
-77.28%
-2.52
+33.95%
-3.81
+11.29%
-4.30
Purchase Of PPE
-4.46
-77.28%
-2.52
+33.95%
-3.81
+11.29%
-4.30
Capital Expenditure
-4.46
+22.61%
-5.77
-32.54%
-4.35
-1.28%
-4.30
Net Investment Purchase And Sale
—
—
—
—
Sale Of Investment
—
—
—
—
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-3.60
Purchase Of Business
—
0.00
0.00
+100.00%
-3.60
Net Intangibles Purchase And Sale
0.00
+100.00%
-3.25
-501.85%
-0.54
0.00
Purchase Of Intangibles
0.00
+100.00%
-3.25
-501.85%
-0.54
0.00
Net Other Investing Changes
-5.71
-104.41%
129.49
+2500.54%
-5.39
+52.73%
-11.41
Financing Cash Flow
-0.26
+99.60%
-64.25
-352.75%
25.42
+230.86%
7.68
Cash Flow From Continuing Financing Activities
-0.26
+99.60%
-64.25
-352.75%
25.42
+230.86%
7.68
Net Issuance Payments Of Debt
0.00
+100.00%
-50.00
-300.00%
25.00
+400.00%
5.00
Issuance Of Debt
0.00
0.00
-100.00%
70.00
+1300.00%
5.00
Repayment Of Debt
0.00
+100.00%
-50.00
-11.11%
-45.00
0.00
Long Term Debt Issuance
0.00
0.00
-100.00%
70.00
+1300.00%
5.00
Long Term Debt Payments
0.00
+100.00%
-50.00
-11.11%
-45.00
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-50.00
-300.00%
25.00
+400.00%
5.00
Net Common Stock Issuance
-1.67
0.00
0.00
—
Common Stock Payments
-1.67
0.00
0.00
—
Repurchase Of Capital Stock
-1.67
0.00
0.00
—
Proceeds From Stock Option Exercised
0.93
+24.07%
0.75
-35.78%
1.17
-56.35%
2.68
Net Other Financing Charges
0.48
+103.21%
-15.00
-1897.34%
-0.75
—
Changes In Cash
-20.56
-165.67%
31.31
+98.77%
15.75
+183.71%
-18.82
Effect Of Exchange Rate Changes
0.40
+218.40%
0.12
+190.70%
0.04
+108.30%
-0.52
Beginning Cash Position
76.06
+70.45%
44.62
+54.80%
28.82
-40.15%
48.16
End Cash Position
55.89
-26.51%
76.06
+70.45%
44.62
+54.80%
28.82
Free Cash Flow
-14.59
+56.99%
-33.93
-693.78%
-4.27
+62.81%
-11.49
Interest Paid Supplemental Data
0.18
0.00
-100.00%
2.58
+358.54%
0.56
Income Tax Paid Supplemental Data
0.80
+75.82%
0.46
+33.04%
0.34
+3.95%
0.33
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category